Brokerages Set Savara Inc. (NASDAQ:SVRA) Target Price at $10.14

Shares of Savara Inc. (NASDAQ:SVRA) have received an average rating of “Moderate Buy” from the eight ratings firms that are presently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, six have given a buy rating and one has issued a strong buy rating on the company. The average 1 year target price among analysts that have issued a report on the stock in the last year is $10.1429.

Several analysts recently weighed in on the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Savara in a research note on Friday, July 17th. Wall Street Zen downgraded shares of Savara from a “hold” rating to a “sell” rating in a report on Saturday, August 15th.

Savara Trading Down 4.2%

Shares of Savara stock opened at $5.26 on Monday. The company has a market capitalization of $1.08 billion, a price-to-earnings ratio of -9.07 and a beta of 0.29. The company has a quick ratio of 10.13, a current ratio of 10.13 and a debt-to-equity ratio of 0.21. Savara has a 12-month low of $3.19 and a 12-month high of $7.01. The firm’s 50-day moving average price is $5.70 and its two-hundred day moving average price is $5.48.

Savara (NASDAQ:SVRA) last issued its earnings results on Tuesday, August 11th. The company reported ($0.16) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.02). On average, analysts forecast that Savara will post -0.62 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. VR Adviser LLC grew its holdings in Savara by 8.4% during the 4th quarter. VR Adviser LLC now owns 13,740,375 shares of the company’s stock worth $82,854,000 after acquiring an additional 1,059,332 shares during the last quarter. BlackRock Inc. bought a new stake in shares of Savara in the 2nd quarter valued at about $76,966,000. Vanguard Group Inc. increased its stake in shares of Savara by 20.8% in the fourth quarter. Vanguard Group Inc. now owns 10,041,647 shares of the company’s stock valued at $60,551,000 after buying an additional 1,728,453 shares during the period. Nantahala Capital Management LLC raised its position in shares of Savara by 5.4% during the third quarter. Nantahala Capital Management LLC now owns 8,775,375 shares of the company’s stock worth $31,328,000 after acquiring an additional 450,000 shares during the last quarter. Finally, Polar Capital Holdings Plc bought a new stake in Savara in the fourth quarter valued at approximately $50,086,000. Institutional investors and hedge funds own 87.93% of the company’s stock.

About Savara

Savara Inc (NASDAQ:SVRA) is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare respiratory diseases. The company specializes in in-licensing, advancing and potentially bringing to market novel treatments that address severe pulmonary conditions with high unmet medical need.

The company’s lead candidate, Molgradex (recombinant human granulocyte-macrophage colony-stimulating factor, or GM-CSF), is under regulatory review for the treatment of autoimmune pulmonary alveolar proteinosis (PAP), a rare lung disease characterized by the accumulation of surfactant.